The unparalleled surge in digital health adoption during the COVID-19 pandemic has emphasized the potential of mHealth apps and digital therapeutics to prevent, to predict and to treat infectious as well as chronic conditions.Â
Regulatory bodies are expected to develop their current approaches adopting comprehensive evaluation processes that adequately consider mHealth apps and digital therapeutics' specific features.Â
The key findings from a review of the regulatory aspects of mobile health apps and digital therapeutics in the different international contexts will be presented and discussed with international experts from the European Commission, Food & Drug Administration, Italian Public Health Institute (ISS), HTA Agencies and Industry.
All event materials are now available